Astellas to build drug production facility in Ireland

2023-09-14

Preview

来源: Pharmaceutical Technology

The new facility will allow Astellas to expand its capacity and capabilities for aseptic drug products. Credit: JHVEPhoto / Shutterstock.com.

Astellas Pharma is submitting a planning application for the construction of a new drug production facility in Tralee, County Kerry, Ireland.

To be based on the Industrial Development Authority’s greenfield site in Kerry Technology Park, the new facility will involve an investment of €330m.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsSchistosomiasis mansoni Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ... GlobalData

Preview

来源: Pharmaceutical Technology

ReportsEnterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type a... GlobalData

View allCompanies IntelligenceAstellas Pharma IncAstellas B.V.View all

It will allow the company to expand its capacity and capabilities for aseptic drug products.

It will also bolster stable production for supply worldwide and expedite the development and commercialisation of new antibody drugs and other products.

To be constructed on a 44.7-acre site, the three-storey building will feature a total floor area of 17,000m² and a footprint of 7,300m².

Construction is set to start in 2024, with the site operational by 2028.

The new facility will align with the company’s commitment to sustainability, integrating national and international energy and environmental design standards.

The project aims to decrease water usage by 50%, lower operational energy intensity by one-third and achieve zero waste sent to landfill.

Astellas chief manufacturing officer Hideki Shima stated: “Astellas is developing innovative drugs and technologies based on our Focus Area research and development approach, placing patients at the forefront of everything we do.

“With the new facility, Astellas will aim to strengthen our in-house production capacity and capabilities and ensure a stable supply of high-quality Astellas medicines to patients around the world.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构